GL1X · GenesisL1 explorer

UniProt P21404

Capsid protein VP1 (P21404)

Capsid protein VP1 (UniProt P21404): 10 experimental structures on GenesisL1, 6 ligands bound, 80 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.

UniProt
P21404
Protein
Capsid protein VP1
Experimental structures
10
Predicted models
0
Ligands
6
Pockets
80 · 6 records with a druggable one

Structures

10 records of P21404 in the MolNFT archive: 10 experimental, 0 predicted.

EntryTitleMethodChainsLigandsPockets
1D4MThe crystal structure of coxsackievirus A9 to 2.9 a resolutionx-ray diffraction1, 2, 3, 4——
1D4MThe crystal structure of coxsackievirus A9 to 2.9 a resolutionx-ray diffraction1, 2, 3, 4——
3J2JEmpty coxsackievirus A9 capsidelectron microscopyA, B, C——
3J2JEmpty coxsackievirus A9 capsidelectron microscopyA, B, C——
8AW6Expanded Coxsackievirus A9 after 0.01% faf-BSA treatmentelectron microscopyA, B, C—12 (best 0.70)
8S7JCoxsackievirus A9 bound with compound 20 (CL300)electron microscopyA, B, C, DA1H9Q, MYR16 (best 0.80)
9EXICoxsackievirus A9 bound with compound 14 (CL275)electron microscopyA, B, C, DA1H8J, MYR12 (best 0.81)
9FCZCoxsackievirus A9 bound with compound 17 (CL301)electron microscopyA, B, C, DA1IB2, MYR14 (best 0.81)
9FO2Coxsackievirus A9 bound with compound 15 (CL278)electron microscopyA, B, C, DA1IEI, MYR11 (best 0.81)
9FP5Coxsackievirus A9 bound with CL213.electron microscopyA, B, C, DPLM, MYR15 (best 0.78)

Ligands

  • MYR · Myristic acid · in 5 records
  • A1H8J · 4-[(4-methylpiperazin-1-yl)methyl]-N-[[4-(trifluoromethyl)phenyl]methyl]aniline · in 1 record
  • A1H9Q · ~{N}-[(4-methoxyphenyl)methyl]-4-[(4-methylpiperazin-1-yl)methyl]aniline · in 1 record
  • A1IB2 · ~{N}-[(3-fluorophenyl)methyl]-4-[(4-methylpiperazin-1-yl)methyl]aniline · in 1 record
  • A1IEI · ~{N}-[(4-fluorophenyl)methyl]-4-[(4-methylpiperazin-1-yl)methyl]aniline · in 1 record
  • PLM · Palmitic acid · in 1 record

Elsewhere

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.